by University of California, Los Angeles Credit: Pixabay/CC0 Public Domain Research led by scientists at UCLA Jonsson Comprehensive Cancer Center found that responses to a type of immunotherapy called PD-1 checkpoint blockade in patients with advanced melanoma depended on whether or not they had previously received another immunotherapy—CTLA-4 blockade—as well as other factors. Their findings, based on...
by Aalto University T cells recognise harmful invaders in the body from their molecular signatures and are able to form an immunological memory for future incursions. Credit: Matti Ahlgren/Aalto University Researchers at Aalto University, the University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center have studied how a completely new treatment option affects the immune...
The company said that in a phase 2 clinical trial, the vaccine, when combined with immunotherapy drug Keytruda, reduced the risk of recurrence by 44%. A Moderna building in Cambridge, Mass., on May 18, 2020.Bill Sikes / AP fileLink copied Dec. 13, 2022, 10:13 AM MSTBy The Associated Press Moderna’s stock soared Tuesday after the Covid-19...
by United European Gastroenterology Credit: Unsplash/CC0 Public Domain Eating a Mediterranean diet rich in fiber, mono-unsaturated fatty acids and polyphenols, has been associated with improved immunotherapy response rates and progression-free survival in advanced melanoma patients, a new study presented today at UEG Week 2022 has found. Experts anticipate that the diet will play an important...
Megan Brooks January 05, 2022 For untreated advanced melanoma, the fixed-dose combination of relatlimab and nivolumab is a “game changer that we have been waiting 10 years for,” Hussein Tawbi, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, told Medscape Medical News about today’s publication of the phase 2/3 RELATIVITY-047 trial. Progression-free survival (PFS) was “essentially double” with...
DANA-FARBER CANCER INSTITUTE Higher percentage of patients treated with nivolumab and ipilimumab in clinical trial reach the six-and-a-half-year survival mark than those treated with either drug alone. BOSTON – In the longest follow-up results from a clinical trial of combination immunotherapy for metastatic melanoma, investigators report that nearly half the patients who received the drugs nivolumab and ipilimumab were...
